CDC Independent Valuation - 30 June 2024

Infratil Limited 5 Market Lane, PO Box 320, Wellington, New Zealand Tel +64-4-473 3663 www.infratil.com
4 July 2024

CDC Independent Valuation - 30 June 2024

The 30 June 2024 independent valuation of Infratil’s investment in CDC shows an increase of A$466
million over the three months since the 31 March 2024 valuation.
Infratil’s 48.25% investment in CDC is now valued at between A$4,159 million to A$4,940 million (with
a midpoint of A$4,524 million), up from A$3,783 million to A$4,368 million (with a midpoint of A$4,058
million) at the end of March 2024.
The increase in valuation reflects the updated CDC pipeline disclosed at the announcement of
Infratil’s June 2024 equity raising. CDC is currently in advanced negotiations with customers for over
400MW of capacity across multiple sites, expected to come online over the next 4-5 years. As a
result, CDC is developing a new Sydney data centre campus at Marsden Park, contributing to an
increase in CDC’s future build capacity by 661MW to 1,197MW and total planned capacity of
1,887MW (up from 1,220MW in March 2024). This expanded pipeline demonstrates the favourable
market tailwinds for data centres and the strong progress in CDC’s customer discussions. Total
operating capacity has increased by 34MW since 31 March 2024, reflecting CDC’s first data centre
development in Melbourne (Brooklyn 1) commencing operations.
Region
Status
Build Capacity
(MW), as at 31
March 2024
Build Capacity
(MW), as at 30 June
2024
Canberra
Operating 117 117
Sydney
Operating 123 123
Melbourne
Operating
- 34
Auckland
Operating
28 28
Total Operating Capacity 268 302
Canberra Under Construction 39 39
Sydney
Under Construction 158 158
Melbourne
Under Construction 151 121
Auckland
Under Construction 68 70
Total Under Construction Capacity 416 388
Canberra Future Build 91 90
Sydney Future Build
269 872
Melbourne Future Build 98 157
Australian Expansion Future Build 36 36
Auckland Future Build 42 42
Total Future Build Capacity 536 1,197
Total Capacity 1,220 1,887

The blended cost of equity used in the valuation has increased from 11.25 % to 11.50% between
March and June 2024. This primarily reflects an increase in gearing as a result of higher forecast debt
levels as CDC continues investment in its expanded development pipeline. The increase in gearing is
partially offset by a decrease in the asset-specific risk premium, driven by the valuer’s assessment of
the status of CDC’s customer discussions and their overall view of CDC’s ability to deliver on its
forecast growth. T he risk-free rate has remained constant at 3.90%.
From a funding perspective, this valuation reflects the guidance provided as part of Infratil’s June
2024 equity raising, with Infratil’s pro-rata share of equity contributions to CDC at approximately
A$600 million over the next two years. This represents an increase of ~A$150 million (on the same

2
pro-rata basis) relative to what was assumed in the March 2024 valuation. CDC intends to continue
accessing a range of debt markets to provide further funding for its expanded development pipeline.
Net debt as at 30 June 2024 was A$3 ,262 million.
CDC’s FY2025 full-year EBITDAF guidance of A$320 million to A$330 million remains unchanged.
Enquiries should be directed to:

Mark Flesher
Investor Relations
mark.flesher@infratil.com

3
Appendix 1 – Independent Valuation Summary 30 June 2024
Valuation Methodology 31 March 2024 30 June 2024
Primary valuation
methodology
DCF using FCFE (with a cross check to comparable companies and
precedent transactions), surplus and underutilised land at cost
Forecast period 15 years (2039)
15 years (2039)
Enterprise value
A$11,118m
A$12,723m
Equity value
A$8,412m
(IFT share A$4,058m)
A$9,376m
(IFT share A$4,524m)
Key Valuation Assumptions
Risk free rate 3.90% 3.90%
Asset beta 0.55 0.55
Cost of equity
(blended rate) reflecting the
assessed risk of the spectrum of
CDC’s activity, from operating data
centres with contracted revenues
through to developing projects
without contracted revenues.
11.25% 11.50%
Terminal growth rate 2.5% 2.5%
Long term EBITDA margin 85% 85%
Capex
Future capex reflects CDC’s
published development pipeline
Valuation assumes no
development beyond 2031
Valuation assumes no
development beyond 2033